paediatrics Brussels 17

Contemporaneous Evolution of Systemic Therapy in High Risk Neuroblastoma

Target Therapies -Crizotinib D,F Epigenetic Modifiers -HDAC H , ATR

Differentiation Therapy -Cis-retinoic acidB Immunothera py -Anti-GD2, IL2, GMCSF C

HD chemo +abmt

inhibitor I Targeted

Immunotherapy -Antigen directed

CART E,G Intensified TransplantF